Cencora, Inc. (NYSE:COR) Receives $277.90 Consensus Target Price from Brokerages

Cencora, Inc. (NYSE:COR) has been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $277.90.

A number of equities research analysts have commented on COR shares. JPMorgan Chase & Co. raised their price objective on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Mizuho started coverage on Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a report on Wednesday. Evercore ISI raised their target price on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Finally, Wells Fargo & Company raised their target price on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a report on Wednesday, January 29th.

Insider Buying and Selling

In other Cencora news, CAO Lazarus Krikorian sold 2,000 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the sale, the chief accounting officer now directly owns 20,154 shares in the company, valued at $5,241,249.24. The trade was a 9.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Robert P. Mauch sold 4,970 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total value of $1,267,350.00. Following the completion of the sale, the chief executive officer now owns 51,070 shares in the company, valued at approximately $13,022,850. The trade was a 8.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,648 shares of company stock worth $3,382,462. 10.80% of the stock is owned by company insiders.

Institutional Trading of Cencora

Hedge funds have recently made changes to their positions in the company. Hickory Asset Management Inc. bought a new stake in shares of Cencora in the fourth quarter valued at $572,000. Sylvest Advisors LLC purchased a new stake in Cencora during the 4th quarter worth about $1,105,000. Insight Wealth Strategies LLC boosted its stake in Cencora by 124.6% in the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock worth $4,549,000 after purchasing an additional 11,232 shares during the period. Cerity Partners LLC boosted its stake in Cencora by 10.1% in the 3rd quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock worth $8,881,000 after purchasing an additional 3,610 shares during the period. Finally, Vontobel Holding Ltd. grew its holdings in Cencora by 46.9% during the 4th quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company’s stock valued at $1,403,000 after buying an additional 1,995 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Trading Down 0.3 %

Shares of Cencora stock opened at $260.87 on Wednesday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. Cencora has a 52 week low of $214.77 and a 52 week high of $263.70. The stock has a 50 day moving average price of $245.81 and a two-hundred day moving average price of $238.70. The stock has a market capitalization of $50.59 billion, a PE ratio of 37.11, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities analysts anticipate that Cencora will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.84%. Cencora’s dividend payout ratio (DPR) is currently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.